Business
Viveve Announces Regulatory Approval for Viveve(R) System in South Korea
Viveve Announces Regulatory Approval for Viveve(R) System in South Korea.
About this update from Viveve Medical, Inc.
[{"type":"text","content":"\nViveve Announces Regulatory Approval for Viveve(R) System in South Korea\n\nViveve Announces Regulatory Approval for Viveve(R) System in South Korea\n\n\nViveve System -- Painless Out-Patient Procedure to Treat Vaginal Laxity -- Now Approved for Marketing in 26 Countries Around the World\n\nSUNNYVALE, CA--(Marketwired - August 04, 2016) - Viveve Medical, Inc. (\"Viveve\") (NASDAQ: VIVE), a medical technology company focused on women's health, today announced that the company has received regulatory approval for the sale of the Viveve System from the Ministry of Food and Drug Safety in South Korea. Previously, Viveve announced an exclusive distribution partnership for marketing the Viveve System with JOYMG, Co., Ltd (\"JOYMG\"), a leading distributor of medical devices in South Korea.\"The receipt of market approval in South Korea represents another important milestone in our commercialization of the Viveve System in Asia and our quest to make this clinically proven treatment available to the millions of women around the world who are living with vaginal laxity,\" said Patricia Scheller, chief executive officer of Viveve, adding \"South Korea represents a major global market for women's health treatments, and we expect to rapidly build our commercial presence there through our partnership with JOYMG.\" About Viveve Viveve Medical, Inc., is a women's health company passionately committed to advancing new solutions to improve women's overall well-being and quality of life. The company's lead product, the internationally patented Viveve System, is a non-surgical, non-ablative medical device that remodels collagen and restores tissue with only one treatment session. The Viveve System treats the condition of vaginal laxity that can result in decreased physical sensation and sexual satisfaction. Physician surveys indicate that vaginal laxity is the number one post-delivery physical change for women, being more prevalent than weight gain, urinary incontinence or stretch marks. The Viveve Treatment uses patented, reverse-thermal gradient radiofrequency technology to restore vaginal tissue in one 30-minute out-patient treatment in a physician's office. The Viveve System has received regulatory approval in many countries throughout the world and is available through physician import license in Japan. It is currently not available for sal...